UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 18, 2007

SurModics, Inc.

(Exact name of Registrant as Specified in its Charter)

Minnesota
(State or Other Jurisdiction of Incorporation)

0-23837 (Commission File Number)		41-1356149 (IRS Employer Identification No.)

9924 West 74^th Street
Eden Prairie, Minnesota 55344
(Address of Principal Executive Offices and Zip Code)

(952) 829-2700
(Registrant’s telephone number, including area code)

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

		o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
		o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
		o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
		o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

Item 2.02 Results of Operations and Financial Condition.

     On July 18, 2007, SurModics, Inc. issued a press release announcing the results for the quarter and nine months ended June 30, 2007. The copy of the full text of the press release is furnished as Exhibit 99.1 to this report.

Item 9.01 Financial Statements and Exhibits.

(a)		Financial Statements: None.
(b)		Pro forma financial information: None
(c)		Shell company transactions: None
(d)		Exhibits: 99.1 Press Release dated July 18, 2007.

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

EXHIBIT INDEX
to
FORM 8-K

SURMODICS, INC.

Date of Report:		Commission File No.:
July 18, 2007		0-23837

Exhibit No.		ITEM
99.1		Press Release dated July 18, 2007.

•

First license of SurModics’ proprietary ophthalmology implant technology signed with Merck

•

Revenue of $17.8 million, down 2% year-over-year and up 2% sequentially

•

Record non-CYPHER-related revenue, up 19% year-over-year and up 11% sequentially

•

12th consecutive quarter of growth in non-CYPHER revenue

•

Record revenue in “In Vitro” and “Hydrophilic and Other” operating segments

•

Strong year-over-year revenue growth in two of our three operating segments:

	•		Hydrophilic and Other — up 25%
	•		In Vitro — up 28%
	•		Drug Delivery — down 33%

•

Operating income of $7.5 million

•

Net income of $5.6 million

•

Diluted EPS of $0.31

•

5 new licenses signed with SurModics customers, bringing fiscal 2007 total to 21

•

3 new customer product classes launched by our customers, bringing fiscal 2007 total to 13

“Revenue from sources other than Cypher continues to be strong. We achieved record non-Cypher revenue in the third quarter, and have maintained non-CYPHER revenue growth for 12 consecutive quarters,” said Bruce Barclay, President and CEO. “Further, we again delivered strong performance and record revenue in our In Vitro and Hydrophilic and Other operating segments this quarter. While drug eluting stent related revenue declined, we are pleased with the results generated in the rest of our diversified business portfolio. In fact, despite J&J’s 14% sequential decrease in drug eluting stent sales compared with the March quarter, total revenue for SurModics actually increased 2% sequentially.”

“This was an historic quarter for SurModics,” continued Barclay. “As previously announced, we signed a new agreement with Merck, which represents the first license agreement related to SurModics’ I-vation™ sustained drug delivery implant technology in ophthalmology. This agreement, which provides the framework to become the largest in the history of SurModics, includes the potential for up to $308 million in license fees and development milestones alone, as well as R&D fees, royalties, and revenue from manufacturing clinical and commercial products for Merck. However, since the agreement was finalized near quarter end, we did not recognize any Merck related revenue in the third quarter. This new agreement, coupled with our strong non-Cypher revenue, positions us to deliver value to our shareholders well into the future. Most importantly, this agreement allows us to move forward with an exceptional partner on the development and commercialization of this technology, which holds great promise for addressing two of the leading causes of blindness.”

“We made excellent progress toward achieving our fiscal 2007 goals during the third quarter,” added Barclay. “In addition to the ophthalmology license, we signed a development agreement related to our Eureka™ biodegradable drug delivery polymer technology, and we signed a license agreement covering a new cardiovascular drug eluting stent. Finally, with five new licenses during the quarter, we have already exceeded our goal of signing 18 new license agreements during the fiscal year.”

Revenue for the third quarter of fiscal 2007 was $17.8 million, a decrease of 2% from $18.1 million in the year earlier period. Operating income was $7.5 million, a 21% decrease from $9.5 million in the prior year period. Net income was $5.6 million, compared with $6.4 million in the same period last year. Diluted earnings per share was $0.31, compared with $0.34 in the third quarter of fiscal 2006.

For the first nine months of fiscal 2007, revenue was $51.9 million, compared with $52.3 million in the year earlier period. Operating income was $23.7 million, compared with $27.0 million in the prior year period; net income was $17.3 million, compared with $14.0 million in the year earlier period; and diluted earnings per share was $0.95, compared with $0.75 in the first nine months of fiscal 2006. Prior year nine month results include a non-cash impairment loss of $4.7 million on our investment in Novocell.

SurModics’ pipeline continues to represent significant potential. The company signed 5 new licenses in the third quarter, reaching a total of 21 licenses fiscal year to date, equaling last year’s record number of new licenses and surpassing the company’s fiscal 2007 goal of 18 new licenses. Our customers launched 3 new product classes in the marketplace during the quarter, increasing our total to 13 and making progress against our goal of 20 customer product launches in fiscal 2007. As of June 30, 2007, SurModics’ customers had 98 licensed product classes generating royalty revenue, up from 83 in the prior-year period; the total number of licensed product classes not yet launched was 93, compared with 81 in the prior-year period; and major non-licensed opportunities totaled 74, compared with 77 a year ago. In total, SurModics now has 167 potential commercial products in development representing each of the company’s five focus markets — Cardiovascular, Ophthalmology, Orthopedics, Neurology and In Vitro.

SurModics’ cash and investment balance was $94.1 million as of June 30, 2007, with no debt. Operating cash flow for the quarter was $7.1 million and $23.6 million for the first nine months of fiscal 2007.

“SurModics remains in excellent financial condition,” said Phil Ankeny, Senior Vice President and Chief Financial Officer. “We continue to evaluate various alternatives to deploy our cash in support of our strategic initiatives and for the benefit of shareholders. We are pleased to have completed our $35 million share repurchase program last quarter. In the full repurchase program, we retired in excess of one million shares at an average price of $34.76 per share, facilitating a reduction of approximately 5% in total shares outstanding. In addition, our business development pipeline continues to present interesting opportunities that offer excellent ways to grow our business and put our balance sheet to work. The $3.5 million strategic investment made earlier this month in Paragon Intellectual Properties relating to our FINALE prohealing technology is representative of the types of high quality opportunities we seek to identify.”

About SurModics, Inc.
SurModics, Inc. is a leading provider of surface modification technologies in the areas of biocompatibility, site specific drug delivery, biological cell encapsulation, and medical diagnostics. SurModics partners with the world’s foremost medical device, pharmaceutical and life science companies to bring innovation together for better patient outcomes. Recent collaborative efforts include the implementation of SurModics’ Bravo™ drug delivery polymer matrix as a key component of the first-to-market drug-eluting coronary stent. SurModics is also active in the ophthalmology market with a sustained drug delivery system that is currently in human trials for treatment of retinal disease. A significant portion of SurModics’ revenue is generated by royalties earned from the sale of our customers’ commercial products. SurModics is headquartered in Eden Prairie, MN. More information about the company can be found at www.surmodics.com. The content of SurModics’ web site is not part of this release or part of any filings the company makes with the SEC.

Safe Harbor for Forward Looking Statements
Certain statements contained in this press release may be deemed to be forward-looking statements under federal securities laws, and SurModics intends that such forward looking statements be subject to the safe harbor created thereby. SurModics does not undertake an obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact

Phil Ankeny, Senior Vice President and Chief Financial Officer
(952) 829-2700

SurModics, Inc.
Statements of Income
(In thousands, except per share data)

		Three Months Ended								Nine Months Ended
		June 30,								June 30,
		2007				2006				2007				2006
		(Unaudited)								(Unaudited)
Revenue:
Royalties and license fees		$	13,416			$	13,948			$	39,664			$	39,514
Product sales			2,947				2,659				9,054				7,914
Research & development			1,399				1,532				3,147				4,883
Total revenue			17,762				18,139				51,865				52,311
Operating expenses:
Product			1,217				891				3,396				2,441
Research & development			6,200				5,281				17,124				14,935
Sales & marketing			343				348				989				1,052
General & administrative			2,484				2,156				6,644				6,887
Total operating expenses			10,244				8,676				28,153				25,315
Income from operations			7,518				9,463				23,712				26,996
Investment income			1,201				1,102				3,702				2,782
Impairment loss on investment			—				—				—				(4,651	)
Income before income taxes			8,719				10,565				27,414				25,127
Income tax provision			(3,132	)			(4,207	)			(10,161	)			(11,087	)
Net income		$	5,587			$	6,358			$	17,253			$	14,040
Basic net income per share		$	0.31			$	0.34			$	0.95			$	0.76
Diluted net income per share		$	0.31			$	0.34			$	0.95			$	0.75
Weighted average shares outstanding
Basic			17,815				18,570				18,116				18,494
Diluted			17,968				18,725				18,249				18,681

-more-

SurModics, Inc.
Condensed Balance Sheets
(In thousands)

		June 30,				September 30,
		2007				2006
		(Unaudited)
Assets
Current assets:
Cash & investments		$	46,303			$	58,813
Accounts receivable			10,460				14,493
Merck license receivable			20,000				—
Inventories			1,259				952
Other current assets			2,536				1,838
Total current assets			80,558				76,096
Property & equipment, net			11,447				11,686
Long-term investments			47,785				47,758
Other assets			25,068				21,862
Total assets		$	164,858			$	157,402
Liabilities & Stockholders’ Equity
Current liabilities		$	3,483			$	6,753
Deferred revenue (current and long-term)			23,829				4,446
Other liabilities			—				1,000
Total stockholders’ equity			137,546				145,203
Total liabilities & stockholders’ equity		$	164,858			$	157,402

SurModics, Inc.
Condensed Statements of Cash Flows
(In thousands)

		Nine months ended
		June 30,
		2007				2006
		(Unaudited)
Operating Activities
Net Income		$	17,253			$	14,040
Depreciation and amortization			2,923				2,726
Net other operating activities			3,777				7,413
Net change in operating assets and liabilities			(356	)			2,895
Net cash provided by operating activities			23,597				27,074
Investing Activities
Net purchases of property and equipment			(2,018	)			(5,300	)
Net other investing activities			11,261				(26,318	)
Net cash provided (used) by investing activities			9,243				(31,618	)
Financing Activities
Issuance of common stock			2,399				2,377
Repurchase of common stock			(35,030	)			—
Net other financing activities			—				116
Net cash provided (used) by financing activities			(32,631	)			2,493
Net change in cash and cash equivalents			209				(2,051	)
Cash and Cash Equivalents
Beginning of period			3,751				3,921
End of period		$	3,960			$	1,870

# # #